Actively Recruiting
Study of Autologous B7-H3 CAR T Cell Therapy for Previously Treated Extensive-Stage Small Cell Lung Cancer and Refractory Extrapulmonary Neuroendocrine Cancer
Led by National Cancer Institute (NCI) · Updated on 2026-10-29
40
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Small cell lung cancer SCLC is the most deadly form of lung cancer, and extrapulmonary neuroendocrine cancers EP-NEC are rare and aggressive cancers similar to SCLC that occur outside the lungs. Both cancers often have limited treatment options after the disease returns or does not respond to first-line therapy. This Phase I study evaluates a new treatment using B7-H3 chimeric antigen receptor CAR T cell therapy, which modifies a persons immune T cells to target a protein called B7-H3 found on these cancer cells. The study aims to determine the maximum tolerated dose or maximum administered dose and assess disease control in participants with recurrent or refractory SCLC or EP-NEC. Participants will have their T cells collected through a procedure called apheresis, where blood is drawn and T cells are separated and modified to attack B7-H3. Before receiving the modified T cells, participants undergo chemotherapy with cyclophosphamide and fludarabine to prepare their body. The modified T cells are then infused back into the participant through a vein. The study includes dose escalation and expansion phases, and participants may be offered an additional infusion up to two years after the initial treatment. Treatments and assessments are done in a hospital setting. During the study, participants will have clinical assessments, blood tests, imaging scans, and heart function tests to monitor safety and treatment response. Samples of blood and tumors will be collected at various times. Participants will remain under follow-up for up to 15 years to monitor disease progression, response, and long-term safety. The main outcomes measured include the highest dose participants can tolerate without severe side effects and the rate of disease control over time.
CONDITIONS
Brief Title
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
Research Team
S
Stephanie N Hicks
N
Nicholas P Tschernia, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here